d) "Affiliate" and "Associate" shall have the respective --------- --------- meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended and in effect on the date of this...Rights Agreement • July 18th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
EXHIBIT 10.1Lease Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
129,665 SHARES OF COMMON STOCK STOCK PURCHASE AGREEMENT DATED AS OF APRIL 22, 1997 MYRIAD GENETICS, INC. STOCK PURCHASE AGREEMENT THIS AGREEMENT, made as of April 22, 1997, is by and between MYRIAD GENETICS, INC. (the "Company"), a Delaware...Stock Purchase Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research
EXHIBIT 1.1 3,000,000 Shares Myriad Genetics, Inc. COMMON STOCK, $0.01 par value UNDERWRITING AGREEMENT November 21, 2002 Morgan Stanley & Co. Incorporated 1585 Broadway New York, New York 10036 Dear Sirs and Mesdames: Myriad Genetics, Inc., a...Myriad Genetics Inc • November 26th, 2002 • In vitro & in vivo diagnostic substances • New York
SCHEDULE to the Master Agreement dated as of October 8, 1997 betweenMaster Agreement • November 14th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Exhibit 4.5 REGISTRATION RIGHTS AGREEMENT ----------------------------- This Registration Rights Agreement is made and entered into as of October 27, 2000 (this "Agreement"), by and between Myriad Genetics Inc., a Delaware corporation (the "Company"),...Registration Rights Agreement • November 22nd, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
AGREEMENTAgreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
EXHIBIT 10.3 SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
This PURCHASE AGREEMENT (this "Agreement"), dated as of October 27, 2000, --------- is entered into by and between Myriad Genetics Inc., a Delaware corporation with offices at 320 Wakara Way, Salt Lake City, Utah 84108 (the "Company"), and Acqua...Purchase Agreement • November 22nd, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research
Exhibit 10.1 Amendment and Supplement to Collaborative Research and License Agreement This Amendment and Supplement dated as of the 19 of November, 1997, made between Bayer Corporation ("Bayer") an Indiana corporation, having an office at 400 Morgan...License Agreement • February 13th, 1998 • Myriad Genetics Inc • Services-commercial physical & biological research
Exhibit 10.3 AMENDMENT NO. 1 TO MASTER LEASE AGREEMENT DATED OCTOBER 25, 1999 (the "Lease") BY AND BETWEEN MYRIAD GENETICS, INC. ("Lessee") AND COMDISCO LABORATORY AND SCIENTIFIC GROUP, A DIVISION OF COMDISCO HEALTHCARE GROUP, INC. ("Lessor") WHEREAS,...Master Lease Agreement • February 14th, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research
CREDIT AGREEMENT dated as of June 30, 2023 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent ___________________________ JPMORGAN CHASE BANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as...Credit Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
CREDIT AGREEMENT dated as of June 30, 2023 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), among MYRIAD GENETICS, INC., as Borrower, the other Loan Parties party hereto, the Lenders party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Issuing Bank.
WITNESSETH:Standstill Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
CREDIT AGREEMENT dated as of August 31, 2016 among MYRIAD GENETICS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., as Sole Bookrunner and Sole Lead ArrangerCredit Agreement • November 2nd, 2016 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
CREDIT AGREEMENT (this “Agreement”) dated as of August 31, 2016 among MYRIAD GENETICS, INC., a Delaware corporation, the LENDERS from time to time party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
EXHIBIT 10.1 MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.1 PORTIONS OF THE AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR WHICH...Research Agreement • November 14th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research
RECITALS --------Collaboration and License Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Utah
EXHIBIT 1.1 2,000,000 Shares MYRIAD GENETICS, INC. Common Stock $0.01 par value UNDERWRITING AGREEMENTUnderwriting Agreement • March 14th, 2000 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Myriad Genetics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • November 13th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 6,470,588 shares (the “Firm Securities”) and, at the election of the Underwriters, up to 970,588 additional shares (the “Optional Securities”) of common stock, par value $0.01 per share (“Stock”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
MYRIAD GENETICS, INC. INDENTURE Dated as of DEBT SECURITIES TrusteeIndenture • November 8th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
WHEREAS, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of unsecured debentures, notes, bonds or other evidences of indebtedness (the “Securities”) in an unlimited aggregate principal amount to be issued from time to time in one or more series as provided in this Indenture; and
AndPromotion Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
EXHIBIT 10.1 ------------ MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.1 PORTIONS OF THE AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE...Patent and Technology License Agreement • April 24th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • Texas
EXHIBIT 10.36 RESEARCH COLLABORATION AND LICENSE AGREEMENTResearch Collaboration and License Agreement • September 29th, 1997 • Myriad Genetics Inc • Services-commercial physical & biological research • New York
Myriad Genetics, Inc. 7,000,000 Shares of Common Stock Underwriting AgreementMyriad Genetics Inc • November 4th, 2005 • In vitro & in vivo diagnostic substances • New York
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,000,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,050,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock.” The Stock, including the Shares, will have attached thereto rights (the “Rights”) to purchase from the Company, upon the occurrence of certain events, a unit consisting of one one-hundredth of a share of the Company’s Series A Junior Participating Preferred Stock, $0.01 par value per
RECITALSLicense Agreement • May 15th, 2001 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
MYRIAD GENETICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
This Agreement sets forth the terms of the incentive stock option (“ISO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Employee”).
PLEDGE AND SECURITY AGREEMENTPledge and Security Agreement • July 6th, 2023 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
THIS PLEDGE AND SECURITY AGREEMENT (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) is entered into as of June 30, 2023 by and among MYRIAD GENETICS, INC., a Delaware corporation (the “Borrower”), MYRIAD GENETICS LABORATORIES, INC., a Delaware corporation, MYRIAD WOMEN’S HEALTH, INC., a Delaware corporation, ASSUREX HEALTH, INC., a Delaware corporation, GATEWAY GENOMICS, LLC, a Delaware limited liability company, any additional entities which become parties to this Security Agreement by executing a Security Agreement Supplement hereto in substantially the form of Annex I hereto (such additional entities, together with the Borrower, Myriad Genetics Laboratories, Inc., Myriad Women’s Health, Inc., Assurex Health, Inc. and Gateway Genomics, LLC, each a “Grantor”, and collectively, the “Grantors”), and JPMorgan Chase Bank, N.A., in its capacity as administrative agent (the “Administrative Agent”) for the
NEXUS ON GRAND LEASELease • February 28th, 2024 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • California
This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company ("Landlord"), and MYRIAD GENETICS, INC., a Delaware corporation ("Tenant").
Exhibit 10.4 BIOTECH EQUIPMENT SCHEDULE SCHEDULE NO. 001 DATED THIS DECEMBER 31, 1998 TO MASTER LEASE AGREEMENT DATED AS OF DECEMBER 31, 1998 LESSOR & MAILING ADDRESS: LESSEE & MAILING ADDRESS:...Myriad Genetics Inc • February 12th, 1999 • Services-commercial physical & biological research
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 7th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this ___ day of __________, by and between MYRIAD GENETICS, INC., a Delaware corporation (the “Corporation”), and ___________________________________________________ (“Agent”).
Exhibit 10.2 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT is made as of the 30th day of September, 1999, by and between Myriad Genetics, Inc. (the "Company"), a Delaware corporation with primary offices at 320 Wakara Way, Salt Lake City, Utah...Subscription Agreement • November 15th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research • Delaware
Myriad Genetics, Inc. 3,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 9th, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • New York
Myriad Genetics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriter”) 3,000,000 shares of Common Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriter, up to an additional 450,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are herein referred to as the “Stock.” The Stock, including the Shares, will have attached thereto rights (the “Rights”) to purchase from the Company, upon the occurrence of certain events, a unit consisting of one one-hundredth of a share of the Company’s Series A Junior Participating Preferred Stock, $0.01 par value per share, at a purchase price of $300.00 per unit. The Rights are to be issued pursuant to a Rights Agreement, dated July 17, 2001, which
Executive Retention AgreementRetention Agreement • November 7th, 2018 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah
THIS EXECUTIVE RETENTION AGREEMENT (this “Agreement”), by and between Myriad Genetics, Inc., a Delaware corporation (the “Company”), and ________________________ (the “Executive”), is made as of ___________, (the “Effective Date”).
MEMORANDUM OF LEASEA Lease Agreement • November 12th, 1998 • Myriad Genetics Inc • Services-commercial physical & biological research
Exhibit 10.1 MASTER LEASE AGREEMENT dated as of December 31, 1998 ("AGREEMENT") THIS AGREEMENT, is between GENERAL ELECTRIC CAPITAL CORPORATION its successors and assigns, if any ("LESSOR") and MYRIAD GENETICS, INC. ("LESSEE"). Lessor has an office at...Master Lease Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research
EXHIBIT 10.6 ANNEX B TO SCHEDULE NO. 001 TO MASTER LEASE AGREEMENT DATED AS OF DECEMBER 31, 1998 STIPULATED LOSS AND TERMINATION VALUE TABLE * --------------------------------------------Master Lease Agreement • February 12th, 1999 • Myriad Genetics Inc • Services-commercial physical & biological research
